T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

被引：5

作者：

McCoon, Patricia

Lee, Young S.

Kelley, Robin Kate

Guthrie, Violeta Beleva

Wu, Song

Bien, Stephanie A.

Negro, Alejandra

He, Philip

Kurland, John

Barrett, J. Carl

Pilataxi, Fernanda

Ching, Steven

Abou-Alfa, Ghassan K.

机构：

[1] AstraZeneca, Translat Med, Waltham, MA USA

[2] AstraZeneca, Translat Med, Gaithersburg, MD USA

[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[4] Adapt Biotechnol, Seattle, WA USA

[5] AstraZeneca, Gaithersburg, MD USA

[6] Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4087

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4087

引用

页数：2